Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA), seeking approval of IMAAVY® ...

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company ...

Breakthrough Therapy status for rilzabrutinib in wAIHA addresses the lack of approved treatments for this rare and life-threatening condition.

Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic ...

The Silent Thief of Vitality Dr Randhir Singh dr.randhirlo@gmail.com If your dog appears lethargic, skips meals, or lacks energy, it may not be temporary. Anemia, a condition where the dog lacks ...

Sanofi’s estimated fair value has been adjusted slightly, with the price target moving from €99.14 to €98.49. Analysts link this small change to a more balanced view of the stock, weighing execution ...

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the ...

Sanofi SNY announced that the FDA has granted Breakthrough Therapy designation to Wayrilz (rilzabrutinib), a novel oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of ...

On February 9, 2026, Sanofi announced that its oral BTK inhibitor rilzabrutinib, marketed as Wayrilz for immune thrombocytopenia, received U.S. FDA breakthrough therapy designation and orphan drug ...

Alkermes plc announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live ...

Poor sleep is linked to significantly higher rates of self-injury, suicidal thoughts and aggression among autistic children and adults, according to a new peer-reviewed study by researchers at the ...